See what questions
a doctor would ask.
The pharmaceutical company Santarus has received FDA approval for the first and only immediate-release oral proton pump inhibitor to be used by critically ill patients. It reduces the risk of upper gastrointestinal bleeding and provides short term treatment for active benign gastric ulcers. The product is called ZEGERID. The product allows for an immediate, higher dose product. Lower dose ZEGERID has already been approved for use as a short term treatment for active duodenal ulcers, heartburn, erosive esophagitis and other gastroesophageal reflux disease symptoms. The most common side effects associated with the drug include headache, diarrhea and abdominal pain. The medication should not be taken by people who are trying to restrict their sodium intake and by people who suffer from metabolic alkalosis and hypocalcemia.
Source: summary of medical news story as reported by Businesswire
About: Drug company receives FDA approval for high dose GERD treatment
Date: 22 December 2004
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City